Source link : https://www.newshealth.biz/health-news/new-combination-drug-for-endometrial-cancer-approved-in-eu/
The European Commission has approved a combination of an immunotherapy agent with a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of certain patients with primary advanced or recurrent endometrial cancer. Imfinzi (durvalumab, AstraZeneca) plus chemotherapy as a first-line treatment followed by Lynparza (olaparib, AstraZeneca) plus Imfinzi was approved for patients with mismatch repair proficient […]
Author : News Health
Publish date : 2024-08-14 18:08:23
Copyright for syndicated content belongs to the linked Source.
Categories